Key facts
- This page summarizes James E. Bradner's Form 4 filing for AMGEN INC (AMGN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 May 2024, 18:59.
James E. Bradner - 07 May 2024 Form 4 Insider Report for AMGEN INC (AMGN)
- Reporting relationship
- EVP, R&D, & Chief Sci. Officer
- Issuer ticker
- AMGN
- Reported as of
- 07 May 2024
- Net transaction value
- +$5,586,481
- SEC form
- 4
- Accepted by SEC
- 09 May 2024, 18:59:37 UTC
- Prior SEC filing
- 12 Feb 2024
- Next SEC filing
- 08 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James E. Bradner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Bradner filed Form 4 for AMGEN INC (AMGN) on 09 May 2024.
Change
- Previous filing in this sequence was filed on 12 Feb 2024.
- Current net transaction value: +$5,586,481.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMGN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,863
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 25,438
- Date
- 07 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMGN
transaction
Derivative
Nqso (Right to Buy)
Award
- Transaction value
- $5,586,481
- Shares
- +18,603
- Change %
- Price
- $300.30
- Shares after
- 18,603
- Date
- 07 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,603
- Exercise price
- $300.30
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.
Footnote F2
These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028; and 2,863 RSUs which will vest in installments of 944 on 5/7/2026, 945 on 5/7/2027, and 974 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
Footnote F3
These shares include 182 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Footnote F4
These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.